Discovery and optimization of p38 inhibitors via computer-assisted drug design.

Integration of computational methods, X-ray crystallography, and structure-activity relationships will be disclosed, which lead to a new class of p38 inhibitors that bind to p38 MAP kinase in a Phe out conformation.

[1]  Gulzar Ahmed,et al.  5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase. , 2005, Journal of medicinal chemistry.

[2]  C. Dominguez,et al.  p38 Inhibitors: beyond pyridinylimidazoles , 2005 .

[3]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[4]  S. Laufer,et al.  Small molecular anti‐cytokine agents , 2006, Medicinal research reviews.

[5]  Yoshiki Tsuchiya,et al.  Regulatory mechanisms and functions of MAP kinase signaling pathways , 2006, IUBMB life.

[6]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[7]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  C. Dominguez,et al.  p38 MAP kinase inhibitors: many are made, but few are chosen. , 2005, Current opinion in drug discovery & development.

[9]  J. Ashwell.  The many paths to p38 mitogen-activated protein kinase activation in the immune system , 2006, Nature Reviews Immunology.

[10]  Luhua Lai,et al.  LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .

[11]  S. Whittaker,et al.  Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. , 2006, Journal of medicinal chemistry.

[12]  J. Madwed,et al.  Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). , 2003, Journal of medicinal chemistry.

[13]  J. Saklatvala.  The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. , 2004, Current opinion in pharmacology.

[14]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[15]  E. A. O'neill,et al.  Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. , 1999, Journal of Medicinal Chemistry.

[16]  R. M. Scrowston,et al.  7-Substituted benzo[b]thiophenes and 1,2-benzisothiazoles. Part 2. Chloro and nitro derivatives , 1984 .